A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02053792 |
|
Recruitment Status :
Completed
First Posted : February 4, 2014
Results First Posted : July 14, 2022
Last Update Posted : July 14, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study will examine the long-term safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children and adults with severe hemophilia B. The study will include subjects who have not previously been treated with Factor IX products, subjects who previously completed a CSL-sponsored rIX-FP lead-in study and subjects requiring major non-emergency surgery who have not previously completed a CSL-sponsored rIX-FP lead-in study.
A surgical prophylaxis substudy will examine the efficacy of rIX-FP in subjects with hemophilia B who are undergoing non-emergency major or minor surgery. An additional substudy will examine the safety and PK of subcutaneous (SC) administration of rIX-FP.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hemophilia B | Biological: rIX-FP | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 97 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B |
| Actual Study Start Date : | February 6, 2014 |
| Actual Primary Completion Date : | June 2, 2021 |
| Actual Study Completion Date : | June 2, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: rIX-FP
Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years. The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP. For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter. The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data. |
Biological: rIX-FP
Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) |
- Total Number of Participants Who Developed Inhibitors Against Factor IX (FIX) [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). For PUPs: up to 3 years or the time it takes to achieve 50 EDs. ]
- Mean Incremental Recovery of a 50 IU/kg Dose of CSL654 in Previously Untreated Patients (PUPs) [ Time Frame: Approximately 30 minutes after infusion of CSL654 ]Incremental Recovery: The increase in plasma concentration per IU/kg of factor administered.
- Total Annualized Bleeding Rate (ABR) by Prophylaxis Regimen in Previously Treated Patients (PTPs) [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Spontaneous ABR by Prophylaxis Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Average Amount of CSL654 (rIX-FP) Consumed Per Month Per Subject During Routine Prophylaxis Treatment. [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). For PUPs: up to 3 years or the time it takes to achieve 50 EDs. ]
- Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and the Percentage of Participants With at Least One CSL654-related TEAE [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). For PUPs: up to 3 years or the time it takes to achieve 50 EDs. ]
- Number of Participants With Investigator's Overall Clinical Assessment of Hemostatic Efficacy for the Treatment of Major Bleeding Events With CSL654 in PUPs [ Time Frame: Up to 3 years or the time it takes to achieve 50 EDs ]The investigator will rate the efficacy of the rIX-FP treatment based on a hemostatic efficacy four point rating scale of excellent, good, moderate, or poor/no response.
- Total ABR for On-demand Regimen vs. 14-Day Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Spontaneous ABR for On-demand Regimen vs. 14-Day Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Total ABR for Subjects >=12 Years: 7-Day Regimen vs. 14-Day Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Spontaneous ABR for Subjects >=12 Years: 7-Day Regimen vs. 14-Day Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Total ABR for Subjects >=12 Years: 7-Day Regimen vs. (10 or 14)-Day Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
- Spontaneous ABR for Subjects >=12 Years: 7-Day Regimen vs. (10 or 14)-Day Regimen in PTPs [ Time Frame: For PTPs: up to 5 years or the time it takes to achieve 100 exposure days (EDs). ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 70 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Main study inclusion criteria:
For previously treated subjects, either:
- Completed a CSL-sponsored rIX-FP (CSL654) study, including study CSL654_3001 [NCT01496274] or study CSL654_3002 [NCT01662531].
Or:
- Scheduled to have a major non-emergency surgery within approximately 8 weeks from the anticipated date of receiving the first rIX-FP injection.
- Not previously completed a CSL-sponsored rIX-FP lead-in study.
- Male, 12 to 70 years of age.
- Documented severe hemophilia B (FIX activity of ≤ 2%), or confirmed at screening by the central laboratory.
- Subjects who have received FIX products (plasma-derived and / or recombinant FIX) for > 150 exposure days (EDs), confirmed by their treating physician.
- No confirmed history of FIX inhibitor formation at screening by the central laboratory
For previously untreated subjects:
- Male, up to 18 years of age.
- Documented severe hemophilia B (FIX activity of ≤ 2%), or confirmed at screening by the central laboratory.
- Never previously been treated with FIX clotting factor products (except previous exposure to blood components).
- No confirmed history of FIX inhibitor formation
Surgery substudy inclusion criterion:
- Must require non-emergency surgery
Subcutaneous substudy inclusion criteria:
- Male, at least 18 years of age.
- Subjects currently enrolled in Study CSL654_3003
- Subjects who have received rIX-FP for ≥ 100 EDs (single-dose cohorts) or for ≥ 50 EDs (repeated-dose cohort)
Exclusion criteria:
Main study exclusion criteria:
- Currently receiving a therapy not permitted during the study.
- Any issue that, in the opinion of the investigator, would render the subject unsuitable for participation in the study.
For subjects who have previously completed a CSL-sponsored rIX-FP study:
- Unwilling to participate in the study for a total of 100 exposure days.
For subjects requiring major non-emergency surgery who have not previously completed a CSL-sponsored rIX-FP lead-in study:
- Known hypersensitivity (ie, allergic reaction or anaphylaxis) to any FIX product or hamster protein.
- Known congenital or acquired coagulation disorder other than congenital FIX deficiency.
- Currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment.
- Low platelet count, kidney or liver disease.
- Human immunodeficiency virus positive with a CD4 count < 200/mm3.
For previously untreated subjects:
- Known congenital or acquired coagulation disorder other than congenital FIX deficiency (except for vitamin K deficiency of the newborn).
- Known kidney or liver dysfunction or any condition which, in the investigator's opinion, place the patient at unjustifiable risk.
The surgical substudy does not have any additional exclusion criteria, although subject(s) in France will not be eligible for the surgery sub-study.
Subcutaneous substudy exclusion criteria:
- Intravenous use of rIX-FP within 14 days of subcutaneous administration of rIX-FP.
- Life-threatening bleeding episode or major surgery during the 3 months prior to substudy entry
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02053792
Show 42 study locations
| Study Director: | Program Director | CSL Behring |
Documents provided by CSL Behring:
| Responsible Party: | CSL Behring |
| ClinicalTrials.gov Identifier: | NCT02053792 |
| Other Study ID Numbers: |
CSL654_3003 2012-005489-37 ( EudraCT Number ) |
| First Posted: | February 4, 2014 Key Record Dates |
| Results First Posted: | July 14, 2022 |
| Last Update Posted: | July 14, 2022 |
| Last Verified: | July 2022 |
|
Hemophilia A Hemophilia B Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases |
Coagulation Protein Disorders Hemorrhagic Disorders Genetic Diseases, Inborn Genetic Diseases, X-Linked |